Literature DB >> 21884478

A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites.

Syouji Orimi1, Katsunari Mizuno, Michihito Narahara, Hideko Umakosi, Masanori Kaihara, Masami Hashimoto.   

Abstract

We examined appropriate flow rates for high collection rates of Total Protein (TP) and Albumin (Alb) and a change of IL-6 concentrations in the cell-free and concentrated ascites reinfusion therapy (CART) process. No significant changes were observed in IL-6 concentration in the ascites storage test and the circulatory stimulation test. However, it was confirmed that the quantity of IL-6 in the ascites decreased by means of filtration and concentration. In some cases, it quickly reached high concentration rates at a higher flow rate (200 mL/min) setting, but clogging or pressure increase has occurred in the hollow fiber filter. Therefore, it was concluded that a low flow rate (50 mL/min) setting was best and provides safer conditions for filtration and concentration in order to collect TP and Alb effectively and reuse it as autologous protein, which is the primary objective of CART.
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884478     DOI: 10.1111/j.1744-9987.2011.00973.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  6 in total

1.  Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.

Authors:  Rumi Hanada; Naosuke Yokomichi; Chihiro Kato; Kazumi Miki; Sachiko Oyama; Tatsuya Morita; Ryoko Kawahara
Journal:  Support Care Cancer       Date:  2017-11-22       Impact factor: 3.603

2.  Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.

Authors:  Osamu Maeda; Takafumi Ando; Kazuhiro Ishiguro; Osamu Watanabe; Ryoji Miyahara; Masanao Nakamura; Kohei Funasaka; Furukawa Kazuhiro; Yuichi Ando; Hidemi Goto
Journal:  Mol Clin Oncol       Date:  2014-07-04

3.  Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.

Authors:  Tadashi Namisaki; Yuki Tsuji; Mitsuteru Kitade; Nobuyuki Yorioka; Yukihisa Fujinaga; Yasuhiko Sawada; Norihisa Nishimura; Koh Kitagawa; Takashi Inoue; Hiroaki Takaya; Kosuke Kaji; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.

Authors:  Yosuke Yamada; Keita Inui; Yuuta Hara; Kazuaki Fuji; Kosuke Sonoda; Koji Hashimoto; Yuji Kamijo
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

5.  Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.

Authors:  Misato Tsubokura; Yuko Adegawa; Minoru Kojima; Ryuji Tanosaki; Ryuzaburo Ohtake; Yuki Kase; Nao Iwashita; Moemi Kasane; Saori Nakabayashi; Sayaka Takeuchi; Ken Kato; Narikazu Boku; Yukihide Kanemitsu; Takuji Okusaka; Hiroyuki Fujimoto; Kan Yonemori; Hiroto Ishiki; Kimihiko Kawamura; Eriko Satomi; Hiromichi Matsushita
Journal:  BMC Cancer       Date:  2022-03-14       Impact factor: 4.430

6.  Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.

Authors:  Norio Hanafusa; Ayako Isoai; Tomoaki Ishihara; Tetsuya Inoue; Ken Ishitani; Taiju Utsugisawa; Toshihiko Yamaka; Tetsuya Ito; Hiroshi Sugiyama; Atsushi Arakawa; Yosuke Yamada; Yasuo Itano; Hirokazu Onodera; Ryosuke Kobayashi; Naoko Torii; Toyoko Numata; Taihei Kashiwabara; Yoshihiro Matsuno; Michio Kato
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.